AbilityPharma closes €7 million round for metastatic pancreatic cancer drug ABTL0812
AbilityPharma closes €7 million round to fully fund its international Phase 2b clinical trial with the antitumor drug ABTL0812 in pancreatic cancer patients.
Svetoslava Georgieva Carles Dom Shermaine Tilley Sara Secall Spain Ministry Of Science Life Sciences
Source: asebio.com